Answers are grounded in this paper and cite their sources.
Background: The role of donor-recipient human leukocyte antigen (HLA) mismatch as a risk factor for developing primary graft dysfunction (PGD) after lung transplantation is not well understood. We describe a novel association between increased donor-recipient HLA mismatch and grade 3 PGD after bilateral lung transplantation.Methods: We retrospectively evaluated donor and recipient demographic data, co-morbidities, intraoperative interventions and outcomes in 99 consecutive adult patients undergoing primary bilateral lung transplantation. The primary outcome of this study was grade 3 PGD at 72 hours. Secondary outcomes included intensive care and hospital lengths of stay and mortality. Results: Eighteen patients (18%) met criteria for grade 3 PGD at 72 hours postoperatively. More non-Caucasian recipients (27.8% vs. 7.4%, p=0.026), and more patients with interstitial lung disease (72.2% vs 43.2%, p=0.031) developed grade 3 PGD. The use of inhaled epoprostenol (OR 4.38, 95% CI: 1.02-20.16, p=0.048), increased HLA mismatches (OR 2.85, 95% CI: 1.31-7.45, p=0.017) and the use of each 250mL unit of PRBCs during the intraoperative period (OR 0.77, 95% CI: 0.58-0.97, p=0.048) were independently associated with grade 3 PGD. Patients diagnosed with grade 3 PGD spent significantly longer time in the intensive care unit (22 days [6;74 days] vs. 7 days [2;83 days], p=<0.001) and hospital (30.5 days [10;83 days] vs. 18 days [3;97 days], p=0.012), and survival was significantly worse for those with PGD3 at 72 hours (log-rank p=0.009).Conclusion: Our data indicate, for the first time, that HLA donor-recipient mismatch is an independent risk factor for developing grade 3 PGD at 72 hours after bilateral lung transplantation.
No takes yet. Share an insight, caveat, or question.
Tjörvi E. Perry (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: